Time-point | T-2 | T-1 | T0 | T1 | T2 | T3 | T4 |
---|---|---|---|---|---|---|---|
Pre-screening | |||||||
Informed consent for pre-screening | X | ||||||
SAGE | X | ||||||
PD-CFRS | X | X | X | X | X | ||
MRI safety screening | X | ||||||
Alcohol abuse screening (CAGE-AID) | X | ||||||
Eligibility screening | |||||||
Montreal Cognitive Assessment | X | X | X | X | X | ||
ICD diagnostic criteria | X | X | |||||
SAPS-PD† | X | ||||||
Beck depression inventory | X | X | X | X | X | ||
Hoehn & Yahr stage | X | X | X | ||||
Enrolment and allocation | X | ||||||
Intervention | |||||||
Cognitive training | ←→ | ||||||
Active control condition | ←→ | ||||||
Assessments | |||||||
Neuropsychological assessment | |||||||
1 | Tower of London | X | X | X | X | X | |
Montreal Cognitive Assessmenta | X | X | X | X | |||
Pentagon copy | X | X | X | X | X | ||
1/2 | Stroop Color Word Test | X | X | X | X | X | |
1 | COWAT (‘letter fluency’) a | X | X | X | X | X | |
2 | WAIS-III digit span | X | X | X | X | X | |
3 | Rey Auditory Verbal Learning Testb | X | X | X | X | X | |
3 | Location Learning Testc | X | X | X | X | X | |
4 | Boston naming test | X | X | X | X | X | |
4 | Category fluency | X | X | X | X | X | |
5 | Rey Complex Figure Test | X | X | X | X | X | |
5 | Visual Form Discrimination Test | X | X | X | X | X | |
Questionnaires and interviews | |||||||
CFQ | X | X | X | X | X | ||
Apathy scale | X | X | X | X | X | ||
Parkinson anxiety scale | X | X | X | X | X | ||
QUIP-RS | X | X | X | X | X | ||
NZPAQ-SF | X | X | X | X | X | ||
Credibility/expectancy questionnaire | X | ||||||
Motor symptom assessments | |||||||
UPDRS-III - motor score | X | X | X | ||||
Medication use | |||||||
Levodopa equivalent daily dosage | X | X | X | X | X | ||
Neuroimaging* | |||||||
MP-RAGE | X | X | |||||
3D PSIR | X | X | |||||
fMRI - resting state | X | X | |||||
DTI | X | X |